Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
Physical function decline is an increasingly recognised concern among individuals with long-term conditions such as Type 2 ...
Fintel reports that on October 29, 2025, Guggenheim maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a ...
OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent ...
Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...
Use of GLP-1 receptor agonists did not appear to affect esophageal function among patients with type 2 diabetes, according to ...
Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...
Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...
Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...
Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...
Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if ...
As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback